tenofovir + emtricitabine + maraviroc

This is a combination of three antiretroviral drugs used in the management and prevention of HIV-1 infection. Tenofovir and emtricitabine are both nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase, thereby blocking viral replication. Maraviroc is a CCR5 antagonist that prevents HIV from entering host cells by blocking the CCR5 co-receptor on CD4+ T cells. This combination has been studied for use as pre-exposure prophylaxis (PrEP) and as part of antiretroviral therapy regimens, though it does not have an established fixed-dose formulation or brand name currently approved for clinical use[2][6]. The combination leverages two mechanisms—reverse transcriptase inhibition and entry inhibition—to provide broad antiviral activity.